Mechanisms of flushing due to niacin and abolition of these effects

Journal of Clinical Hypertension

Volumn 11, Issue 11, 2009, Pages 685-689

  Sood, Aditya ^a   Arora, Rohit ^a  

^a Chicago Medical School North Chicago Veterans Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; G PROTEIN COUPLED RECEPTOR; LAROPIPRANT; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE;

CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HUMANS; INDOLES; NIACIN; PRURITUS;

EID: 70449476500     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1559-4572.2008.00050.x     Document Type: Review

References (41)

1. Canner PL, Berge KG, Wenger NK. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
2. Benyo Z, Gille A, Bennett C. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006, 70:1844-1849.
3. Carlson LA. Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol 2006, 21:336-344.
4. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 2006, 3:144-153.
5. Brown BG, Zhao XQ, Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
6. Meyers CD, Carr MC, Park S. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003, 139:996-1002.
7. Capuzzi DM, Guyton JR, Morgan JM. Efficacy and safety of an extended-release niacin (Niaspan): a long term study. Am J Cardiol 1998, 82:74U-81U.
8. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998, 82:29U-41U.
9. Menon RM, González MA, Adams MH. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 2007, 47.
10. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004, 58:706-713.
11. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005, 65:2719-2740.
12. Knopp RH, Alagona P, Davidson M. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
13. Carlson LA, Hanngren A. Initial distribution in mice of H3-labeled nicotinic acid studied with autoradiography. Life Sci 1964, 3:867-871.
14. Ding RW, Kolbe K, Merz B. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989, 46:642-647.
15. Fumagalli R, Gey KF, Carlson LA. Pharmacokinetics of nicotinic acid and some of its derivatives. Metabolic Effects of Nicotinic Acid and Its Derivatives 1971, 33-49. In, eds, Bern, Switzerland, Hans Huber Publishers
16. Mrochek JE. Metabolic responses of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976, 22:1821-1827.
17. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 2003, 60:S9-S14.
18. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000, 86:35L-40L.
19. Soga T, Kamohara M, Takasaki J. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003, 303:364-369.
20. Tunaru S, Kero J, Schaub A. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:353-355.
21. Wise A, Foord SM, Fraser NJ. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003, 278:9869-9874.
22. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet 2004, 363:1892-1894.
23. Pike NB, Wise A. Identifcation of a nicotinic acid receptor. Is that the molecular target for the oldest lipid lowering drug?. Curr Opin Investig Drugs 2004, 5:271-275.
24. Benyo Z, Gille A, Kero J. GPR109A (PUMA-G/HM74A) mediates nicotinic acid induced flushing. J Clin Invest 2005, 115:3634-3640.
25. Tunaru S, Kero J, Schaub A. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003, 9:352-355.
26. Meyers CD, Liu P, Kamannaa VS. Nicotinic Acid Induces Secretion of Prostaglandin D2 in Human Macrophages: An In vitro Model of the Niacin Flush http://www.elsevier.com/locate/atherosclerosis, Available online 1 September 2006.
27. Maciejewski-Lenoir D, Richman JG, Hakak Y. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006, 126:2637-2646.
28. Dubrac S, Stoitzner P, Pirkebner D. Peroxisome proliferator-activated receptor-activation inhibits langerhans cell function. J Immunol 2007, 178:4362-4372.
29. Kamanna VS, Vo A, Kashyap ML. Nicotinic acid: recent developments. Curr Opin Cardiol 2008, 23(4):393-398.
30. Andersson RG, Aberg G, Brattsand R. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 1977, 41:1-10.
31. Svedmyr N, Heggelund A, Aberg G. Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol Toxicol (Copenh) 1977, 41:397-400.
32. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006, 60(6):707-715.
33. Whitney EJ, Krasuski RA, Personius BE. A randomized control trial of a strategy for increasing high-density lipoprotein cholesterol levels: effecs on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
34. Niaspan Prescribing Information http://www.niaspan.com, . Accessed January 2, 2008
35. Dunn RT, Ford MA, Rindone JP. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995, 2:478-480.
36. Jungnickel PW, Maloley PA, Vander Tuin EL. Effect of two aspirin pretreatment regimens on niacin induced cutaneous reactions. J Gen Intern Med 1997, 12:591-596.
37. Whelan AM, Price SO, Fowler SF. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992, 34:165-168.
38. Wilkin JK, Wilkin O, Kapp R. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982, 31(4):478-482.
39. Lai E, Lepeleire ID, Crumley TM. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype. Clin Pharmacol Ther 2007, 81(6):849-857.
40. Lai E, Wenning LA, Crumley TM. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008, 83(6):840-847.
41. Paolini JF, Mitchel YB, Reyes R. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008, 101(5):625-630.